Immuno-Oncology Gene Expression Analysis with NanoString powered by Canopy Biosciences
Predict responsiveness to PD-1/PD-L1 inhibitors with the Tumor Inflammation Signature

The Tumor Inflammation Signature assesses the expression pattern of 18 genes known to be associated with response to PD-1/PD-L1 inhibitors

Includes 4 Areas of Immune Biology:
- IFN-γ-responsive genes related to antigen presentation
- Chemokine expression
- Cytotoxic activity

18-Gene Tumor Inflammation Signature

- CCL5
- CXCL9
- CD27
- CD8A
- CXCR6
- IOL1
- STAT1
- TIGIT
- LAG3
- PD-L2/PDCD1LG2
- PD-LA/CD274
- CD276
- HLA-DQA1
- HLA-E
- PSMB10
- HLA-DRB1
- CMKLR1
- NKG7

Heatmap showing Tumor Inflammation Signature and responsiveness to pembrolizumab. Rows represent patients and columns genes. The “R” indicates whether the patient was a responder to pembrolizumab.